Perfusion Medical is an emerging biopharmaceutical company developing life-saving cardiovascular therapies focused on shock and ischemic conditions. Its lead candidate PM-208 aims to restore microvascular perfusion, resolve ischemia, and protect vital organs. Preclinical data suggest potential to improve survival, speed recovery, and reduce long-term comorbidities in conditions like hemorrhagic shock, cardiogenic shock, and acute kidney injury.